These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 10397530)

  • 21. Antibodies to HIV-1 gp41 recognize synthetic peptides of human IFN-alpha and IFN-beta.
    Bai Y; Zhao Y; Yu T; Dierich MP; Chen YH
    Int Arch Allergy Immunol; 2000 Feb; 121(2):170-2. PubMed ID: 10705228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent.
    Yu H; Alfsen A; Tudor D; Bomsel M
    Cell Calcium; 2008 Jan; 43(1):73-82. PubMed ID: 17553560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1).
    Neurath AR; Strick N; Jiang S
    Virology; 1992 May; 188(1):1-13. PubMed ID: 1373549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120.
    Pintér C; Siccardi AG; Longhi R; Clivio A
    AIDS Res Hum Retroviruses; 1995 May; 11(5):577-88. PubMed ID: 7576914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage.
    Dimonte S; Babakir-Mina M; Mercurio F; Di Pinto D; Ceccherini-Silberstein F; Svicher V; Perno CF
    Virus Res; 2012 Sep; 168(1-2):73-83. PubMed ID: 22732432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.
    Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J
    FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology.
    Pintér C; Siccardi AG; Lopalco L; Longhi R; Clivio A
    AIDS Res Hum Retroviruses; 1995 Aug; 11(8):971-80. PubMed ID: 7492444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on the mechanism of complement-mediated inhibition of antibody binding to HIV gp41.
    Hidvégi T; Prohászka Z; Ujhelyi E; Thielens NM; Dierich MP; Hampl H; Arlaud G; Nagy K; Füst G
    Clin Exp Immunol; 1993 Dec; 94(3):490-3. PubMed ID: 8252810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion of an immunogenic human immunodeficiency virus (HIV) envelope synthetic peptide to a tolerogen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein.
    Haynes BF; Arthur LO; Frost P; Matthews TJ; Langlois AJ; Palker TJ; Hart MK; Scearce RM; Jones DM; McDanal C
    J Exp Med; 1993 Mar; 177(3):717-27. PubMed ID: 7679708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A common immunological epitope existing between HIV-1 gp41 and human interferon-alpha and -beta.
    Chen YH; Dierich MP
    Immunobiology; 1998 Feb; 198(4):333-42. PubMed ID: 9562860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The amino-terminal peptide of HIV-1 gp41 interacts with human serum albumin.
    Gordon LM; Curtain CC; McCloyn V; Kirkpatrick A; Mobley PW; Waring AJ
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1145-56. PubMed ID: 8312056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.
    Haro I; Gómara MJ; Galatola R; Domènech O; Prat J; Girona V; Busquets MA
    Biochim Biophys Acta; 2011 Jun; 1808(6):1567-73. PubMed ID: 21377446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two interaction modes of the gp41-derived peptides with gp41 and their correlation with antimembrane fusion activity.
    Ryu JR; Jin BS; Suh MJ; Yoo YS; Yoon SH; Woo ER; Yu YG
    Biochem Biophys Res Commun; 1999 Nov; 265(3):625-9. PubMed ID: 10600471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The envelope glycoprotein of HIV-1 gp120 and human complement protein C1q bind to the same peptides derived from three different regions of gp41, the transmembrane glycoprotein of HIV-1, and share antigenic homology.
    Stoiber H; Thielens NM; Ebenbichler C; Arlaud GJ; Dierich MP
    Eur J Immunol; 1994 Feb; 24(2):294-300. PubMed ID: 7507842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mode of interaction between the HIV-1-neutralizing monoclonal antibody 2F5 and its epitope.
    Fiebig U; Schmolke M; Eschricht M; Kurth R; Denner J
    AIDS; 2009 May; 23(8):887-95. PubMed ID: 19414989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Membrane-specific antibodies induced by liposomes can simultaneously bind to HIV-1 protein, peptide, and membrane lipid epitopes.
    Beck Z; Karasavvas N; Matyas GR; Alving CR
    J Drug Target; 2008 Aug; 16(7):535-42. PubMed ID: 18686123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of C1 with HIV-1.
    Thielens NM; Bally IM; Ebenbichler CF; Dierich MP; Arlaud GJ
    Behring Inst Mitt; 1993 Dec; (93):165-70. PubMed ID: 8172563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection.
    Hovanessian AG; Briand JP; Said EA; Svab J; Ferris S; Dali H; Muller S; Desgranges C; Krust B
    Immunity; 2004 Nov; 21(5):617-27. PubMed ID: 15539149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.